Shire Granted EU Conditional Marketing Authorisation For Natpar[®▼] (Parathyroid Hormone) For The Treatment Of Patients With Chronic Hypoparathyroidism

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), the first recombinant human protein with the full length 84-amino acid sequence of endogenous parathyroid hormone (PTH). Natpar will be the first and only approved hormone therapy indicated as adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.

Source:
prnewswire.com/news-releases/shire-granted-eu-conditional-marketing-authorisation-for-natpar-parathyroid-hormone-for-the-treatment-of-patients-with-chronic-hypoparathyroidism-620439673.html

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: